International Edition

Tuesday

January, 24, 2017

Breaking News, World News and Taiwan News.
About Us
Subscribe
Advertise
Contact Us

Gilead ordered to pay Merck

NEW YORK -- A U.S. jury has ordered pharmaceutical giant Gilead Sciences to pay US$2.5 billion to competitor Merck in a patent infringement case involving a drug used to treat hepatitis C, the two companies said.

A federal jury in Delaware on Thursday sided with Merck subsidiary Idenix, which claimed that Gilead's blockbuster sofosbuvir drug and its derivatives, sold under the labels Solvadi et Harvoni, violated one of its patents.

"The patent at issue in this case facilitated significant advances in the treatment of patients with HCV infection and was appropriately granted," Merck said in a statement.

Write a Comment
CAPTCHA Code Image
Type in image code
Change the code
 Receive our promos
 Respond to this email
MOST POPULAR OF THIS SECTION
Subscribe  |   Advertise  |   RSS Feed  |   About Us  |   Career  |   Contact Us
Sitemap  |   Top Stories  |   Taiwan  |   China  |   Business  |   Asia  |   World  |   Sports  |   Life  |   Arts & Leisure  |   Health  |   Editorial  |   Commentary
Travel  |   Movies  |   TV Listings  |   Classifieds  |   Bookstore  |   Getting Around  |   Weather  |   Guide Post  |   Student Post  |   Terms of Use  |   Sitemap
  chinapost search